Species |
Human |
Protein Construction |
Expressed with an N-terminal Met.
IFN-α 1b [Cys24-Glu189 (Ala137Val)] Accession # P01562 |
|
Purity |
> 96% as analyzed by SDS-PAGE > 96% as analyzed by HPLC |
Endotoxin Level |
< 1 EU/μg of protein by LAL method |
Biological Activity |
Fully biologically active when compared to standard. The specific activity determined by an anti-viral assay is no less than 1.0 × 108 IU/mg. |
Expression System |
E. coli |
Theoretical Molecular Weight |
19.5 kDa |
Formulation |
Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4, 4% mannitol, 1% HSA. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
Target Background |
At least 23 different variants of IFN-alpha are known. The individual proteins have molecular masses between 19-26 kDa and consist of proteins with lengths of 156-166 and 172 amino acids. All IFN-alpha subtypes possess a common conserved sequence region between amino acid positions 115-151 while the amino-terminal ends are variable. Many IFN-alpha subtypes differ in their sequences at only one or two positions. Naturally occurring variants also include proteins truncated by 10 amino acids at the carboxy-terminal end. |
Synonyms |
Interferon-α1b; IFN-α1b |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.